This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 03
  • /
  • Results of Phase III Murano trial of Venclexta + R...
Drug news

Results of Phase III Murano trial of Venclexta + Rituxan in chronic lymphocytic leukaemia published in NEJM.- AbbVie/Roche/Genentech.

Read time: 1 mins
Last updated:23rd Mar 2018
Published:23rd Mar 2018
Source: Pharmawand

Results from the Phase III Murano trial of Venclexta (venetoclax) from AbbVie, and Rituxan (rituximab), from Roche/Genentech, significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), according to data published in the New England Journal of Medicine. The results show that after a median follow-up period of 23.8 months, progression-free survival (PFS) was significantly higher in patients taking venetoclax/rituximab (with 32 events of progression or death in 194 patients) than in the bendamustine�rituximab group (114 events in 195 patients).

The two-year rates of progression-free survival were 84.9 percent and 36.3 percent, respectively. The rate of grade 3 or 4 neutropenia was higher in the venetoclax�rituximab group than in the bendamustine�rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine.

See: "Venetoclax�Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia" John F. Seymour et al. N Engl J Med 2018; 378:1107-1120 DOI: 10.1056/NEJMoa1713976

Comment: Data from the MURANO study will be submitted to global health authorities, including the FDA, which has granted Breakthrough Therapy Designation for Venclexta in combination with Rituxan for the treatment of relapsed or refractory CLL based on promising results from the Phase Ib M13-365 study.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights